Oral administration of (S)-LCM (10 mg/kg for 7 days) reduced CRMP2 phosphorylation, preserved CRMP2–ANT interaction (Supplementary Figures S1 and S2) [20], and protected AD mitochondria from Ca2+-induced PTP activation (Figure 3C,D). Here, DPYSL2 is linked to Alzheimer disease.